Filtered By:
Drug: Copaxone
Management: National Institute for Health Research (NIHR)
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1 results found since Jan 2013.
4-Year Follow-up of Delayed-Release Dimethyl Fumarate Treatment in Relapsing-Remitting Multiple Sclerosis (RRMS): Integrated Magnetic Resonance Imaging (MRI) Outcomes From DEFINE, CONFIRM, and the ENDORSE Extension Study (P3.160)
CONCLUSIONS: Reduced frequency of new MRI lesions is maintained over 4 years among patients continuing therapy. Switching from placebo to delayed-release DMF, patients demonstrated MRI outcomes similar to those with delayed-release DMF in DEFINE/CONFIRM. Together with clinical efficacy and an acceptable safety profile, results support delayed-release DMF as a potential long-term treatment option for relapsing MS.Study Supported by: Biogen IdecDisclosure: Dr. Arnold has received personal compensation for activities with Acorda Therapeutics, Bayer Pharmaceuticals Corporation, Biogen Idec, Coronado Biosciences, EMD Serono, Ge...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Arnold, D., Fox, R., Gold, R., Havrdova, E., Kappos, L., Yousry, T., Zhang, R., Yang, M., Viglietta, V., Sheikh, S., Miller, D. Tags: MS and CNS Inflammatory Disease: Clinical Trials Outcomes Source Type: research
